In thrombolytic therapy, heparinization is useful as it has the function of preventing thrombosis and combating recurrent infarction. However, the need for heparinization depends on the condition. Thrombolytic therapy can be used in the pharmacologic recanalization of thromboembolism in many organs, such as cerebral infarction and myocardial infarction. Currently in the clinical commonly used thrombolytic drugs for urokinase, streptokinase and other non-specific fibrinogen activator. This drug achieves the purpose of thrombolysis by breaking down the fibrin in the thrombus, but cannot break down the fibrinogen in the blood. As the infarction occurs, the localization is in a state of hypercoagulation, thrombolytic drugs can only decompose the formed thrombus, but can not inhibit the continued action of the coagulation process, so anticoagulation and antiplatelet therapy is needed to inhibit the formation of new thrombus to prevent re-occlusion. Heparin is commonly used clinically, so it is also called heparinization. However, it should be noted that the timing of heparinization intervention for myocardial infarction and cerebral infarction is not the same; anticoagulation and thrombolysis cannot be performed if there is a risk of bleeding and intervention or surgery is required within a short period of time. Whether and when to perform anticoagulation needs to be determined by the clinician according to the condition.